Matthew Mildred BSc (Kent) MSc (Lancaster) AORS
HEDS, ScHARR
The University of Sheffield
Regent Court, 30 Regent Street
Sheffield
S1 4DA
UK
Office:
Tel: (+44) (0)114 222 5429
Fax: (+44) (0)114 272 4095
E-mail: m.mildred@sheffield.ac.uk
Biography
I joined ScHARR in October 2009 to continue my work on prostate cancer screening which I undertook as part of my MSc in Operational Research at Lancaster University Management School.
I am currently developing cost-effectiveness models on a number of NICE Multiple Technology Assessments (MTA´s) and completing a Masters of Education in my own time.
Research interests
My research includes assessing the cost-effectiveness of treatments for NICE and pharmaco-economics.
Teaching interests
My teaching interests include Advanced Excel Modelling, Visual Basic, Linear Programming using LINDO and Multi-criteria Decision Analysis (MCDA). I teach modules on the following courses:
MSc in Health Economics & Decision Modelling (HEDM):
- Cost-effectiveness Modelling for Health Technology Assessment
- OR Techniques in Health Resource Allocation
MSc International Health Technology Assessment, Pricing and Reimbursement:
- Building Cost-Effectiveness Models for HTA
Master of Public Health (MPH):
- Dissertation module
Professional activities
- I am an active member of the OR Society.
- As a member of ScHARR-TAG I undertake Technology Assessments for the NIHR Health Technology Assessment Programme.
- I am the HEDS Section representative on the ScHARR IT Functional Working Group.
Current projects
- NICE MTA of Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis. (NICE)
- Modelling NHS carbon emission reduction strategies. (Sheffield Teaching Hospitals Trust)
- NICE MTA of first-line nilotinib (Tasigna) for the treatment of chronic phase CML. (Novartis Pharmaceuticals)
- SMC submission for first-line nilotinib (Tasigna) for the treatment of chronic phase CML. (Novartis Pharmaceuticals)
- NICE MTA of second-line nilotinib (Tasigna) for the treatment of chronic phase CML. (Novartis Pharmaceuticals)
- Option Appraisal of Prostate Cancer Screening. (UK National Screening Committee)
Key publications
- Mildred M, Chilcott J, Hummel S. 2011. The YoungOR Conference (YOR17). A cost-effectiveness model of prostate cancer screening. April 5. [Oral Presentation] Nottingham, UK. [Abstract] [Slides PDF]
- Chilcott J, Mildred M, Hummel S. 2010. The Winter Simulation Conference. Use of the Metropolis-Hastings Algorithm in the Calibration of a Patient Level Simulation of Prostate Cancer Screening. December 6. [Poster Presentation] Baltimore. [Abstract] [Poster PDF]
- Chilcott J, Hummel S, Mildred M. 2010. Option appraisal: screening for prostate cancer. UK National Screening Committee. [UK NSC Website] [Report PDF]